Brugada综合征麻醉管理18年分析:BRUGANAES研究
BRUGANAES研究为西班牙巴塞罗那某三级医院的观察性回顾性项目,纳入2006年1月1日至2023年12月31日接受任何类型麻醉的Brugada综合征患者,分析111例患者共189例次操作。主要结局为麻醉期间及麻醉后30天内恶性室性心律失常和/或心源性猝死的发生,结果显示2例患者术中发生主要结局(占操作1%),而68.3%的操作使用了非推荐药物。
要点
- Brugada综合征患者围术期恶性室性心律失常发生率低(1%的操作)。
- 多数操作(68.3%)使用了丙泊酚、氯胺酮或局部麻醉药等非推荐药物。
- 术中事件包括非推荐药物后心动过缓诱发的室颤及未列有害药物后的短暂室速。
核心结论
- Brugada综合征患者围术期恶性室性心律失常和/或心源性猝死的发生率较低,但多数患者接受了非推荐麻醉药物。
研究设计与样本
- 观察性回顾性项目,纳入2006年1月1日至2023年12月31日西班牙巴塞罗那某三级医院接受任何类型麻醉的Brugada综合征患者,最终分析111例患者共189例次操作。
主要发现
- 全身麻醉占51.3%,镇静占36%,单纯区域/椎管内麻醉占12.7%。
- 非推荐药物(丙泊酚、氯胺酮和局部麻醉药)用于129例次操作(68.3%),包括单次推注和/或持续输注。
- 区域麻醉中硬膜外阻滞占34%(多用于产科),蛛网膜下腔阻滞占31.8%。
- 主要结局发生于2例患者术中(占操作的1%):1例在使用非推荐药物后出现心动过缓诱发的室颤,1例在使用未列为潜在有害的药物后出现短暂室速。
临床怎么用
- 对于Brugada综合征患者,围术期应警惕恶性室性心律失常风险,尽管发生率较低。
- 使用丙泊酚、氯胺酮或局部麻醉药等非推荐药物时需加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Brugada syndrome (BrS) is a genetic disorder that increases the risk of ventricular tachyarrhythmias and sudden cardiac death (SCD). Certain drugs (propofol, local anaesthetics), fever, bradycardia, increased vagal tone and electrolyte imbalances can trigger or worsen BrS arrhythmias. OBJECTIVE: To evaluate the incidence of malignant ventricular arrhythmias during the perioperative period in patients with BrS, hypothesising that common anaesthetic drugs may be safe to use during daily clinical practice. DESIGN: The BRUGANAES study was an observational, retrospective project including BrS patients who underwent various types of anaesthesia. SETTING: BrS patients undergoing any type of anaesthesia intervention from 1 January 2006, to 31 December 2023, from a tertiary hospital in Barcelona. MAIN OUTCOME MEASURES: The primary outcome was the occurrence of malignant ventricular arrhythmias and/or SCD during and up to 30 days postanaesthesia. Secondary outcomes included adverse events during hospitalisation, 30-day readmission rates and 30-day mortality rates. RESULTS: Among 652 BrS patients registered in the hospital, 111 patients and 189 procedures were analysed. General anaesthesia was administered in 51.3% of cases, sedation in 36% and regional/neuraxial anaesthesia exclusively in 12.7%. Overall, nonrecommended drugs (propofol, ketamine and local anaesthetics) were used in 129 (68.3%) procedures, either bolus and/or continuous infusion. Epidural blocks were performed in 34% of regional anaesthesia cases, mostly in obstetrics, and subarachnoid blocks in 31.8%. The primary outcome occurred in two patients intraoperatively (1% of procedures): one with bradycardia-induced ventricular fibrillation after a nonrecommended drug and one with transient ventricular tachycardia after a drug not listed as potentially harmful. CONCLUSION: To date, this is one of the largest cohorts describing the perioperative approach for BrS patients, including a wide range of anaesthesia procedures and drugs. Most of the patients undergoing anaesthesia for an interventional procedure received an anaesthetic drug classified as not recommended.
引用
- Borrell-Vega J, Fernández Font JD, Linares M, et al. Eighteen-year analysis of anaesthetic management in Brugada syndrome: The BRUGANAES study. Eur J Anaesthesiol. 2025. PMID: 39945140. doi:10.1097/EJA.0000000000002146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。